Form 4: Lyell Immunopharma Director Receives Stock Option Grant

Director William J. Rieflin was granted 9,250 stock options in Lyell Immunopharma, Inc. as part of standard equity compensation.

Summary

• Director William J. Rieflin received a grant of 9,250 stock options on June 10, 2026.
• The options have an exercise price of $13.22 per share.
• The options are set to expire on June 9, 2036.
• Vesting occurs on the earlier of the next annual stockholder meeting or the first anniversary of the grant date, contingent on continuous service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries no significant signal regarding company operational health.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market price volatility may impact the future value of the granted options.
• The exercise price of $13.22 may be significantly higher than the current market price, affecting the incentive value.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on director equity compensation.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise, though they are generally neutral events regarding immediate company performance.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with standard corporate governance practices for mid-cap biotechnology firms.
• Equity-based compensation remains the primary vehicle for director remuneration in the life sciences industry.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor potential for future dilution.
• Director: Increased equity stake in the company.

Next Steps

• Vesting of options on the earlier of the next annual meeting or June 10, 2027.

Key Dates

Keywords

Lyell Immunopharma, LYEL, Director Compensation, Stock Options, Insider Transaction, Form 4